Korean J Stroke.
2012 Aug;14(2):62-66.
Stroke Update 2011: New Antithrombotics
- Affiliations
-
- 1Department of Neurology, Severance Institute for Vascular and Metabolic Research, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. kylee@yuhs.ac
Abstract
- Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke.
MeSH Terms
-
Aspirin
Atrial Fibrillation
Benzimidazoles
beta-Alanine
Factor Xa
Humans
Incidence
Intracranial Hemorrhages
Korea
Lactones
Morpholines
Naphthalenes
Propionates
Pyrazoles
Pyridines
Pyridones
Receptors, Thromboxane A2, Prostaglandin H2
Stroke
Thiophenes
Thrombin
Dabigatran
Rivaroxaban
Aspirin
Benzimidazoles
Factor Xa
Lactones
Morpholines
Naphthalenes
Propionates
Pyrazoles
Pyridines
Pyridones
Receptors, Thromboxane A2, Prostaglandin H2
Thiophenes
Thrombin
beta-Alanine
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Organization of Stroke Care System: Stroke Unit and Stroke Center
- Stroke Update: Optimal Blood Pressure Management for Stroke Prevention
- Management of Antithrombotic Therapy for Gastroenterological Endoscopy from a Cardio-Cerebrovascular Physician's Point of View
- Management of Antithrombotics before Endoscopy and Biopsy
- Stroke Update 2011: Stroke Rehabilitation
